The clinical trial data of Firehawk TES are published in The Lancet * – a world leading medical journal.
It is the first time that The Lancet has published clinical trial data of a Chinese medical device.
It is concluded that Firehawk TES is as safe and effective as the “gold standard” Xience EES stent and the high level of clinical outcome of TARGET AC is confirmed.
TARGET: LESS is MORE
The abluminal groove target eluting design provides MORE level of efficacy and safety with LESS dose of drug, the beauty and merits of a BMS and DES combination.
* The Lancet is a world leading medical journal, currently ranked second out of 154 journals in the Medicine, General & Internal subject category with an impact factor of 53.254 according to the 2017 Journal Citation Reports.